Binimetinib (MEKTOVI)

Melanoma, advanced or metastatic, with BRAF V600E or BRAF V600K mutation

Melanoma, advanced or metastatic, with BRAF V600E or BRAF V600K mutation

• Oral: 45 mg twice daily continuously until disease progression or unacceptable toxicity.
• Given in combination with encorafenib

‍

Available as 15 mg film-coated tablets. Tablets contain lactose. Tablets should NOT be crushed or broken. Store at room temperature.

Mitogen-activated Extracellular Kinase (MEK) Inhibitor

Take with or without food

If a dose is missed, patients should be instructed to take it as soon as they can if there are > 6 hours until the next dose. If there are < 6 hours until the next dose, patients should skip the missed dose and resume with the next scheduled dose.

Common: Derious retinopathy/detachment, Visual impairment, Diarrhea, Nausea, Vomiting, Fatigue, ALT increase, AST increase, Creatinine increase, Creatinine phosphokinase increase, Glucose increase, Myopathy, Hyperkeratosis, Rash.

Less Common: Cardiomyopathy/left ventricular dysfunction, Serous retinopathy or retinal detachment, Retinal vein occlusion, Uveitis, Pyrexia, Rhabdomyolysis, Basal cell carcinoma, Cutaneous squamous cell carcinoma, Interstitial lung disease/pneumonitis, Alopecia, Hemorrhage, Hypertension, Venous thromboembolism.

The adverse effects listed above are not exhaustive. Please refer to the relevant product monograph for full details.

Baseline before treatment: Liver function tests, CPK, creatinine, MUGA scan or echocardiogram, CBC & differential, blood pressure, dermatologic evaluation (every 2 months during treatment and up to 6 months after the last dose).

During treatment: Liver function tests, CPK, and creatinine, MUGA scan or echocardiogram, dermatologic evaluation (every 2 months during treatment and up to 6 months after the last dose).

If clinically indicated: CBC & differential, blood pressure.

• This drug can impact or be impacted by metabolic enzymes for absorption and excretion. Many drugs can also affect or be affected by these enzymes, so please consult with pharmacy to assess for interactions.
• Current drug interaction databases should be consulted for more information.

• Avoid in pregnancy and lactation.
• Patients reporting new or worsening visual disturbances such as diminished central vision, blurred vision, or loss of vision should be promptly referred for ophthalmological evaluation.
• Secondary malignancies have been reported with binimetinib including cutaneous squamous cell carcinoma. Skin examination should be performed prior to, during, and after treatment has ended.

BC Cancer. BC Cancer Drug Manual. Binimetinib. Vancouver, British Columbia: BC Cancer Agency. Available at: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Binimetinib_monograph.pdf. Developed December 1, 2022. Accessed January 22, 2024.

Lexicomp. Binimetinib Monograph. In: Lexi-Drugs. Hudson, Ohio: Lexi-Comp, Inc. Available at: https://online-lexi-com.qe2a-proxy.mun.ca/lco/action/doc/retrieve/docid/patch_f/6667976?cesid=7WyRDldvBZG&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dbinimetinib%26t%3Dname%26acs%3Dtrue%26acq%3Dbinim. Updated January 24, 2024. Accessed January 28, 2024.

Cancer Care Ontario. Binimetinib Monograph. Drug Formulary. Toronto, Ontario: Cancer Care Ontario. Available at: https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/74021. Updated July 2023. Accessed January 22, 2024.Pfizer Canada ULC. MEKTOVI® product monograph. Kirkland, Quebec; Updated March 2, 2021